Effectiveness	O
of	O
the	O
Consecutive	O
Alternating	O
Administration	O
Course	O
of	O
a	O
Triple	O
Antiviral	B:C1254351
Combination	O
in	O
Coxsackievirus	O
B3	O
Infections	O
in	O
Mice	B:C0025929
.	O

Anti-enteroviral	B:C1254351
chemotherapeutics	B:C3665472
for	O
clinical	O
use	O
are	O
not	B:C0243095
registered	I:C0243095
so	I:C0243095
far	I:C0243095
,	O
mainly	O
due	O
to	O
the	O
rapid	O
development	O
of	O
drug-	B:C0013203
resistance	I:C0013203
.	O

One	O
of	O
the	O
possible	O
approaches	O
to	O
overcome	O
this	O
problem	B:C0033213
is	O
the	O
use	O
of	O
combined	O
chemotherapy	B:C3665472
.	O

However	O
,	O
its	O
application	O
consisting	O
of	O
simultaneously	O
given	O
drugs	B:C0013227
,	O
is	O
not	O
efficacious	O
because	O
of	O
the	O
development	O
of	O
multiple	O
resistance	O
.	O

Here	O
we	O
present	O
a	O
novel	O
approach	O
for	O
combined	O
application	O
of	O
anti-enteroviral	B:C1254351
compounds	I:C1254351
,	O
consisting	O
of	O
a	O
consecutive	B:C1533734
alternating	I:C1533734
administration	I:C1533734
(	O
consecutive	B:C1533734
alternating	I:C1533734
administration	I:C1533734
)	O
course	O
.	O

consecutive	B:C1533734
alternating	I:C1533734
administration	I:C1533734
was	O
tested	O
on	O
2	O
in	B:C1515657
vivo	I:C1515657
models	I:C1515657
of	O
Coxsackievirus	O
B3	O
infection	O
in	O
newborn	B:C0003065
mice	B:C0025929
at	O
inoculation	O
dose	O
of	O
20	O
MLD50	O
(	O
50	O
%	O
mouse	O
lethal	O
dose	O
)	O
:	O
neurotropic	B:C0042769
(	O
Nancy	B:C0042776
strain	I:C0042776
)	O
and	O
cardiotropic	B:C0042769
(	I:C0042769
Woodruff	I:C0042769
strain	I:C0042769
)	I:C0042769
infections	I:C0042769
.	O

Compounds	B:C1706082
partnering	O
in	O
a	O
triple	O
combination	O
were	O
selected	O
as	O
enterovirus	B:C0014383
(	O
enterovirus	B:C0014383
)	O
replication	B:C0042774
inhibitors	O
with	O
different	O
mode	O
of	O
action	O
-	O
disoxaril	B:C0058467
(	O
a	O
VP1	B:C0042981
blocker	B:C1254351
)	O
,	O
guanidine	B:C0120447
.	I:C0120447

HCl	I:C0120447
(	O
targeting	O
2C	B:C0246875
protein	I:C0246875
)	O
and	O
oxoglaucine	B:C0673446
(	O
attacking	O
3A	O
coding	O
region	O
)	O
.	O

The	O
application	O
of	O
this	O
combination	O
by	O
consecutive	B:C1533734
alternating	I:C1533734
administration	I:C1533734
course	O
resulted	O
in	O
around	O
40	O
and	O
60	O
%	O
survival	O
rate	O
in	O
mice	B:C0025929
infected	B:C3714514
with	O
Nancy	B:C0042776
and	O
Woodruff	B:C0042776
virus	I:C0042776
,	O
respectively	O
,	O
accompanied	O
by	O
a	O
marked	O
lengthening	O
of	O
the	O
mean	O
survival	O
time	O
(	O
MST	O
)	O
.	O

The	O
results	O
obtained	O
are	O
proofs	B:C0335256
for	O
the	O
prospect	O
of	O
the	O
treatment	O
course	O
by	O
a	O
triple	O
combination	O
through	O
the	O
consecutive	B:C1533734
alternating	I:C1533734
administration	I:C1533734
scheme	B:C1519193
as	O
an	O
approach	O
interfering	O
the	O
occurrence	O
of	O
drug	B:C0013203
resistance	I:C0013203
at	O
EV	B:C0014378
infections	I:C0014378
.	O

